UPLYFT For Lymphoma Survivors

Description

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Conditions

Lymphoma, Survivorship

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors

UPLYFT For Lymphoma Survivors

Condition
Lymphoma
Intervention / Treatment

-

Contacts and Locations

Boston

Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma)
  • * Age ≥ 18 years
  • * Interval of 3 months to 24 months from completion of first-line treatment
  • * In complete remission after first line of treatment
  • * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS).
  • * Access to computer (for videoconferencing)
  • * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR mental health clinicians (psychologists, social workers, psychiatrists) ≥ 1 year from completion of clinical training.
  • * Longitudinal clinical care for patients with lymphoma by oncologists OR provision of care for patients with cancer by mental health clinicians
  • * Age \< 18 years
  • * Concurrent other malignancy
  • * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorder (as ascertained from medical record screen).
  • * Age \< 18 years
  • * Concurrent other malignancy
  • * Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
  • * Our study will exclude members of the following special populations:
  • * Adults unable to consent
  • * Individuals who are not yet adults (infants, children, teenagers)
  • * Pregnant women
  • * Prisoners

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Oreofe O Odejide, MD, PhD, PRINCIPAL_INVESTIGATOR, Oreofe_Odejide@dfci.harvard.edu

Study Record Dates

2025-04-30